Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma [Phase 1]
Phase 1 trial investigating riluzole in combination with sorafenib tosylate in patients with advanced solid tumors or melanoma; the study st…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase Ib of L-NMMA and Pembrolizumab [Phase 1]
This completed Phase 1 trial evaluated the combination of L-NMMA with pembrolizumab across multiple cancers, with results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors [Phase 1]
Phase 1 update reporting safety, pharmacokinetics, and preliminary efficacy data for AI-061 in advanced solid tumors across multiple indicat…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations [Phase 2]
Phase 2 study evaluating patient preference for subcutaneous versus intravenous administration of nivolumab and the nivolumab-relatlimab fix…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) [Phase 2]
Phase 2 study compares subcutaneous pembrolizumab coformulated with hyaluronidase alfa (MK-3475A) to intravenous pembrolizumab in multiple t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors [Phase 1, Phase 2]
GEN1042 is being evaluated in a Phase 1/2 safety study with indications across malignant solid tumors, including non-small cell lung cancer,…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) [Phase 1, Phase 2]
Clinical trial update on safety and efficacy of pembrolizumab alone or with investigational agents in first-line advanced melanoma (MK-3475-…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies [Phase 1]
Phase 1 clinical trial update showing termination of a study evaluating the combination of ipilimumab and MGN1703 in patients with advanced …
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma [Phase 2]
Phase 2 trial evaluating oral azacitidine (CC-486) in combination with pembrolizumab (MK-3475) for metastatic melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
This clinical trial update reports results from a study examining peripheral T cell determinants of response and resistance to pembrolizumab…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases [EARLY_Phase 1]
A Phase 1 pilot trial evaluating nivolumab plus either ipilimumab or relatlimab for surgically resectable melanoma with brain metastases has…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers [Phase 1, Phase 2]
This clinical trial update describes a CD70-targeted CAR-T cell therapy using patients' peripheral blood lymphocytes to treat CD70-expressin…
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: Sun Protection and Tanning Awareness in Rural Schools [NA]
A trial evaluating sun protection and tanning awareness in rural schools has completed and results were posted on 2026-04-03. The study was …
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma [Phase 1]
Phase 1 trial update reports proof of concept for TBio-4101 in combination with lymphodepleting chemotherapy and IL-2 for relapsed/refractor…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors [Phase 1]
Phase 1 study assessing safety, tolerability, pharmacokinetics and preliminary efficacy of BAT4706 in patients with advanced solid tumors, i…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma [Phase 2]
A Phase 2 pilot trial evaluating the efficacy and safety of metformin in melanoma has completed. The study focused on patients with metastat…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy [NA]
This completed clinical trial provides mutational analyses of circulating cell-free DNA in a metastatic melanoma patient before and after ch…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma [Phase 1]
Phase 1 trial completed evaluating a tumor necrosis factor (TNF) inhibitor as an immune checkpoint therapy for advanced melanoma. Sponsor: I…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma [Phase 3]
Phase 3 trial update showing completion of a study comparing ABP-206, Amgen's nivolumab biosimilar, with Opdivo (nivolumab) in patients with…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors [Phase 1]
Phase 1 trial evaluating Nanrilkefusp alfa alone and with pembrolizumab in adults with advanced or metastatic solid tumors; the study (NCT04…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Screening for Brain Metastases [Phase 2]
This clinical trial update describes a Phase 2 study on screening for brain metastases in patients with advanced lung cancer or melanoma, wh…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis [Phase 2]
A Phase 2 clinical trial evaluating a combination of binimetinib, encorafenib, and pembrolizumab, with or without stereotactic radiosurgery,…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer [Phase 1]
A Phase 1 study of PF-07921585 alone or with other anti-cancer medicines in multiple cancers has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients [Phase 1]
Phase 1 clinical trial evaluating fecal microbiota transplantation for immune-checkpoint inhibitor–induced diarrhea or colitis in patients w…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma [EARLY_Phase 1]
An early Phase 1 trial evaluating the combination of imiquimod and pembrolizumab in patients with stage IIIB-IV melanoma has completed with …